Infectious Disease Therapy

Sterol reductase gene potential target for Candida albicans treatment

Published in Medical Letter on the CDC and FDA, April 28th, 2002

by Michael Greer, senior medical writer - Researchers in the United States say that the gene that codes for an important enzyme in the Candida albicans sterol pathway could be an effective target for therapeutic agents.

"The incidence of fungal infections has increased dramatically, which has necessitated additional and prolonged use of the available antifungal agents," according to Dr. N. Jia and colleagues at Indiana University, Purdue University and Eli Lilly & Co. in Indianapolis, and the U.S. Centers for Disease Control and Prevention in Atlanta. "Increased resistance to the commonly used antifungal agents, primarily the azoles, has been reported, thus...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2002-04-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry